||PRESS RELEASE - October 28, 2003
Molecular Engines Laboratories Gains Exclusive Access to Ingenium's INGENOtypes(R) Mouse Model for Cancer Gene
Model Represents Novel Opportunity to Understand Function of TSAP6 Gene
PARIS, and MUNICH, Oct. 28 /PRNewswire/ -- Ingenium Pharmaceuticals AG and
Molecular Engines Laboratories (MEL) announced today an agreement under which
MEL gains exclusive rights to Ingenium's INGENOtypes(R) TSAP6 genetic mouse
model. TSAP6 is a gene discovered by MEL's scientific founders to have a role
in cancer tumor reversion. Ingenium discovered the TSAP6 mouse model through
its Deductive Genomics(R) approach, which screens animals with random
alterations in the genome. The model was selected from the screen due to its
specific phenotype. Terms of the agreement were not disclosed.
"Ingenium's expertise in rodent genetics allows us to offer completely
novel disease models that are extremely valuable for functional genomics
research and for target validation and compound profiling," said Michael C.
Nehls, M.D., Ph.D., Chief Executive Officer of Ingenium. "As demonstrated for
the first time with this agreement, Ingenium has the ability to provide these
models on an exclusive license basis, which represents a significant advantage
for companies such as Molecular Engines Laboratories, who are establishing their leadership
position in a particular therapeutic area."
"Molecular Engines Laboratories is further validating its specific approach to cancer,
namely by working on genes that play a role in the cellular reprogramming
process leading to suppression of tumorigenicity," stated Pierre Attali, CEO
of the company. "We believe that TSAP6 is one of these genes and therefore are
very pleased to have complete access to this INGENOtypes(R) model which we
anticipate to play a crucial role in our further target validation studies,"
said Robert Amson and Adam Telerman, founders and CSOs of MEL.
About the INGENOtypes(R) platform
Ingenium has developed and biologically characterized multiple proprietary
mouse models of human disease called INGENOtypes(R). These models represent an
important tool in biomedical research for drug target validation and for
testing therapeutic hypotheses and drug compounds. Ingenium derives its unique
models from its proprietary Deductive Genomics(R) and INGENOtyping(TM)
platforms. INGENOtypes(R) are either completely novel models of human disease
or display modifications of known genes where models have previously not been
The basis of Ingenium's business is its knowledge and expertise in
generating the biological information critical to the discovery, validation
and development of therapeutics. Ingenium's Deductive Genomics(R) technology
combines genome-covering mutagenesis in the murine model system with a
proprietary, therapeutic goal-oriented biological screen. From the breadth of
knowledge generated by Deductive Genomics(R), Ingenium is currently advancing
a pipeline of novel models and biologically validated drug targets in the
areas of inflammatory bowel disease, diabetes/obesity, and neurological
disorders. The company's INGENOtyping(TM) platform offers an alternative to
producing genetically-altered murine models. Ingenium has research partnership
agreements with Elan Corporation, Bayer AG, F. Hoffmann-La Roche Ltd.,
Sequenom Inc., Oxagen Limited and Lynkeus BioTech GmbH, in addition to
numerous international academic collaborations.
Molecular Engines Laboratories (MEL) is a private biotechnology company
whose purpose is to develop novel therapeutics for cancer. MEL's strategy, as
conceived by Drs. Adam Telerman and Robert Amson, is to characterize most of
the genes associated with tumor reversion and to understand their mechanism of
action in order to induce the reversion of malignant cells to suppressed-
phenotype cells. MEL is currently completing a drug discovery program on its
first target, based on tumour reversion process.
Ingenium, INGENOtypes and Deductive Genomics are registered U.S.